CA
VRTX icon

Calton & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Calton & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-774
Closed -$202K – 356
2022
Q1 		$202K Sell
774
-414
-35% -$98.3K 0.06% 330
2021
Q4 		$260K Buy
1,188
+13
+1% +$2.53K 0.07% 296
2021
Q3 		$213K Buy
+1,175
New +$229K 0.05% 365
2018
Q1 		– Sell
-229
Closed -$38K – 1250
2017
Q4 		$38K Buy
+229
New +$33.9K 0.01% 749

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Calton & Associates's VRTX Position: Q2 2022 in Review

Calton & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 774 shares — an estimated $202K sold.

Calton & Associates first reported a position in VRTX in Q4 2017 and held it in 4 quarters. The position peaked at $260K in Q4 2021. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Calton & Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Calton & Associates sold 774 Vertex Pharmaceuticals shares in Q2 2022, an estimated $202K.
  • Calton & Associates first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Calton & Associates's Vertex Pharmaceuticals position peaked at $260K in Q4 2021.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Calton & Associates's 13F filing for Q2 2022, filed 12 Jul 2022.